Tagged with Strategy,

Korea Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains his strategy to expand into the East Asian market and provides his assessment on how established Korean pharmaceutical companies can…

France Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on to cover the operational specifics of the affiliate and shares her insights on the French pharma ecosystem.   When I…

Korea Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi…

Spain Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore, he highlights the international strategy and the role the US market will play in the future, as well as his…

France Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also shares insights into his career and the learnings from the Levothyrox case.   Overall, we are a very important branch…

Spain Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for better collaboration for long-term sustainably of the Spanish healthcare system and breaks down the role of the ClosingGap cluster to…

France Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access and having a diverse product portfolio.   Lyon carries a number of strategic advantages: economically speaking, office spaces are significantly…

France Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to foreign investors under the Macron Presidency. He also speaks out about CDM Lavoisier’s longstanding legacy in France and outlines the…

Spain Javier Alvarado, general manager of Mundipharma Spain, discusses his current priorities and the innovation the company is bringing to the market through a diversified portfolio. Furthermore, he points out the importance of long-term strategic partnerships for the company´s success and his future aspirations for the affiliate.   Of course, none…

China Alan Chen, general manager for Ipsen China, shares the exciting journey of Ipsen in China in the past few years as the third-largest affiliate for the group globally,  upcoming innovative product launches, the reorganization and HR strategy he has headed to take Ipsen China to the next stage of its…

Turkey Uğur Bingöl, general manager of Ibrahim Etem Menarini, speaks of his company’s rapid growth and new product lines. He also describes his take on the Turkish pharmaceutical market and outlines his strategic priorities to continue growing Ibrahim Etem Menarini’s presence in Turkey.   We are committed to the localization movement…

Korea Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market, emphasizing the importance of volume over price. He also concludes that Korea should focus on establishing itself as a leader…